Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition Journal Article


Authors: Foulsham, W.; Edghill, B. Z.; Canestraro, O. D. J.; Makker, V.; Konner, J.; Abramson, D. H.; Francis, J. H.
Article Title: Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition
Abstract: Purpose: To report a case of central retinal vein occlusion (CRVO) in a patient being treated with a fibroblast growth factor receptor (FGFR) inhibitor. Observations: A 54-year-old female patient with endometrial cancer presented with CRVO and cystoid macular edema while receiving lenvatinib/pembrolizumab combination therapy. The patient received treatment with intravitreal bevacizumab, after which her visual acuity improved markedly, permitting the continuation of her chemotherapy regimen without recurrence of ocular adverse events. Conclusions and Importance: Like mitogen-activated protein kinase inhibitors, FGFR inhibitors have the potential to be associated with retinal vein occlusion. In this case, visual recovery was possible with intravitreal anti-vascular endothelial growth factor therapy, and toxicity did not recur with drug reinitiation and continuation over five years of follow-up. © 2022
Keywords: adult; clinical article; middle aged; anamnesis; case report; bevacizumab; cancer combination chemotherapy; drug withdrawal; hypertension; follow up; endometrium cancer; drug inhibition; metastasis; drug effect; drug substitution; blurred vision; eye examination; mitogen-activated protein kinase; optical coherence tomography; visual acuity; amlodipine; subretinal fluid; retina macula cystoid edema; mapk signaling; fibroblast growth factor receptor inhibitor; lenvatinib; human; female; article; pembrolizumab; central retina vein occlusion; central retinal vein occlusion
Journal Title: American Journal of Ophthalmology Case Reports
Volume: 27
ISSN: 2451-9936
Publisher: Elsevier Inc.  
Date Published: 2022-09-01
Start Page: 101657
Language: English
DOI: 10.1016/j.ajoc.2022.101657
PROVIDER: scopus
PMCID: PMC9284313
PUBMED: 35845747
DOI/URL:
Notes: PDF formats the author: Julia Canestraro's name as "O.D. Julia Canestraro" -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Vicky Makker
    265 Makker
  2. Jason Konner
    156 Konner
  3. Jasmine Helen Francis
    256 Francis
  4. David H Abramson
    389 Abramson